Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial

M Safaeian, C Porras, Y Pan, A Kreimer… - Cancer Prevention …, 2013 - AACR
Abstract The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine
efficacy against 12-month HPV16/18 persistent infection was similarly high among women …
被引用次数：242 相关文章

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

M Safaeian, C Porras, Y Pan, A Kreimer, JT Schiller… - 2013 - cabidigitallibrary.org
Abstract The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine
efficacy against 12-month HPV16/18 persistent infection was similarly high among women …

[引用][C] Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

M SAFAEIAN, C PORRAS… - Cancer prevention …, 2013 - pascal-francis.inist.fr
Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1
Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial CNRS Inist Pascal-Francis CNRS …
[PDF] academia.edu

[PDF][PDF] Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

M Safaeian, C Porras, Y Pan, A Kreimer, JT Schiller… - academia.edu
Abstract The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine
efficacy against 12-month HPV16/18 persistent infection was similarly high among women …

Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

M Safaeian, C Porras, Y Pan, A Kreimer… - Cancer Prevention …, 2013 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The Costa Rica HPV16/18 Vaccine Trial (CVT)
showed that four-year vaccine efficacy against 12-month HPV16/18 persistent infection was …

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

M Safaeian, C Porras, Y Pan, A Kreimer… - Cancer Prevention …, 2013 - europepmc.org
Abstract The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine
efficacy against 12-month HPV16/18 persistent infection was similarly high among women …

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial

M Safaeian, C Porras, Y Pan… - Cancer prevention …, 2013 - pubmed.ncbi.nlm.nih.gov
The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine efficacy
against 12-month HPV16/18 persistent infection was similarly high among women who …
[HTML] nih.gov

[HTML][HTML] Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

M Safaeian, C Porras, Y Pan, A Kreimer… - Cancer prevention …, 2013 - ncbi.nlm.nih.gov
Abstract The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine
efficacy against 12-month HPV16/18 persistent infection was similarly high among women …

[引用][C] Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

M SAFAEIAN, C PORRAS… - Cancer …, 2013 - American Association for Cancer …